Pegylated IFNs for chronic hepatitis C: an update
Authors: Grace, Michael J; Cutler, David L; Bordens, Ronald W
Source: Expert Opinion on Drug Delivery, Volume 2, Number 2, 1 March 2005 , pp. 219-226(8)
Publisher: Informa Healthcare
Abstract:For over a decade, IFN-α2 has been the standard treatment for chronic hepatitis C. However, the drug’s rapid clearance and short half-life have led to low rates of sustained virological response. Pegylation is a well-established method of modifying the pharmacological properties of IFNs, causing significant improvements in pharmacokinetics, which in turn lead to improved efficacy. Two pegylated forms of IFN-α2 have been developed: PEG-IFN-α2b and PEG-IFN-α2a, and their efficacy has been established in randomised, -controlled trials. However, the two differ significantly in structure, invitro activity and pharmacological properties, and this may translate into -differences in clinical efficacy. Comparative trials have been initiated that will provide insight into relative importance of pharmacokinetics, bioactivity and dosing regimen.
Document Type: Review Article
Publication date: March 1, 2005